Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
about
Many multiple myelomas: making more of the molecular mayhemMolecular pathogenesis of multiple myeloma: basic and clinical updatesLong-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesInternational staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsEvidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapieSuperior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyCuring myeloma at last: defining criteria and providing the evidence.Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaMolecular pathogenesis of multiple myeloma and its premalignant precursor.Clinical value of molecular subtyping multiple myeloma using gene expression profilingImproving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Suppression of abnormal karyotype predicts superior survival in multiple myeloma.First thalidomide clinical trial in multiple myeloma: a decade.VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myelomaTP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesPrognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Genomics in multiple myeloma.Bortezomib in the front-line treatment of multiple myeloma.Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.How best to use new therapies in multiple myeloma.Kidney disease associated with plasma cell dyscrasiasClinical impact of chromosomal aberrations in multiple myeloma.Bortezomib for previously untreated multiple myeloma.Bortezomib for previously untreated multiple myeloma.The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.Update on risk stratification and treatment of newly diagnosed multiple myeloma.Bortezomib combination therapy in multiple myeloma.
P2860
Q26852892-E7C2BF98-7143-458A-82DA-69CD04E6013CQ27026205-647D55A6-E409-4FF6-A468-A564736D4F6DQ30486842-FB0FB1B7-012B-4BD4-AF6F-A04AAB44AF92Q31154933-D844D2DB-9346-4076-B2B0-FC0E5C67FA00Q33710994-90049A1E-FDEC-41BD-BD6D-1515FB1AE94FQ33718273-A53A619D-4B89-4D6B-A6B2-7695C1F87078Q33884167-26D4F457-AAD1-41ED-BF1D-5251B61D5F07Q33887470-BD4DA6A1-8728-48F6-95B5-94DFE61787C4Q34122646-1025A165-9491-40A0-8040-A51AB68F5B43Q34508313-F3E46E02-BE2B-4AA9-B7C3-DD9494092929Q34890498-EA5AC62A-A088-4B72-8304-355B4C90A470Q34993904-E4E40DFD-4109-4DA3-A8E1-39E1A8B3A1C3Q35266125-DF779CD6-0A04-4DCF-B474-18CF6F91BBDAQ35569350-1550F70A-55D1-4067-8B40-3D9950E1BF22Q35802414-2066F8D8-E2A1-4E93-B25B-320DB516F648Q35881063-3A159C08-EECB-444D-AF70-0E023F206CAAQ35984702-C4DC1E25-431A-466F-8A09-1594364D7D39Q36055752-AD8209DE-71B5-4145-A894-CBF37A996B49Q36290238-A9A62C6B-02B5-43C7-9F7E-96588EE5C6F9Q36540781-9468387B-97B1-401A-AB2C-899C79A2EF25Q36595290-5BB7CD53-CE39-49BA-A7E0-46923BB358E8Q36831389-0D212DC9-909B-4CA3-81C0-512B385155EDQ36835212-45735CEA-6B4F-45D3-8EC4-5D5F2683022EQ36878944-EE6B297F-BD23-40D7-8C93-3892AE8DDAC0Q36910280-799DE539-33EE-46DD-9FB8-AD6B67D70BD1Q36941047-F6110804-3033-4710-BE88-5F244F710A49Q36993367-020DBD45-DC8F-4511-ABF1-C15E38C01AE0Q37037265-EC327746-0BB2-4C29-B97D-90A8CF3D05CFQ37197359-4AB072D4-1DC2-4A54-8711-9184D5B0BF2BQ37202761-209D1C13-7B90-4689-94A6-2D0925B8553AQ37280737-EE2D767B-9911-48E2-A758-6B2904E3B753Q37348247-30543176-1D08-4558-B5B5-D6890A168801Q37723000-C3675CF6-14EE-486F-83A4-FB32DDB28AE0Q37750106-EE9FBC2F-0350-42D1-B147-1F06CFC664B9Q37821077-011E4A0C-7D64-4E17-A3CC-5FCCDC5812CAQ37908155-73D678D6-DE56-4ECD-96A9-4CFAA5EAFD53Q37937699-D6BAFD40-2094-410B-BB81-88CF0127E480Q37946246-3BE8F4A8-DC24-4D24-9736-371A904F5DF4Q37946701-E8643960-FBD2-4048-B9D8-B1D947E4BAAEQ38021041-C0F2863F-C98A-4352-B6C4-1654A97CD6C9
P2860
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Sustained complete remissions ...... mparison with total therapy 2.
@en
type
label
Sustained complete remissions ...... mparison with total therapy 2.
@en
prefLabel
Sustained complete remissions ...... mparison with total therapy 2.
@en
P2093
P2860
P50
P1476
Sustained complete remissions ...... mparison with total therapy 2.
@en
P2093
Guido Tricot
Jeff Haessler
John Crowley
John D Shaughnessy
Mauricio Pineda-Roman
P2860
P304
P356
10.1111/J.1365-2141.2007.06921.X
P407
P577
2008-03-01T00:00:00Z